The frequent presence of TP53 mutations in ovarian cancer has been suggested for almost two decades [2,3] and during this time, approximately 70 publications have described the relationship between TP53 mutation status and clinical outcome [4]. The gene discussed is TP53; the disease is ovarian carcinoma.